Relationships Between Allopurinol Dose, Oxypurinol Concentration and Urate‐Lowering Response—In Search of a Minimum Effective Oxypurinol Concentration [PDF]
The aims of this study were to determine factors that predict serum urate (SU) lowering response to allopurinol and the conversion of allopurinol to oxypurinol, and to determine a minimum therapeutic oxypurinol concentration.
Lisa K. Stamp +8 more
doaj +4 more sources
Allopurinol and oxypurinol differ in their strength and mechanisms of inhibition of xanthine oxidoreductase [PDF]
Xanthine oxidoreductase is a metalloenzyme that catalyzes the final steps in purine metabolism by converting hypoxanthine to xanthine and then uric acid. Allopurinol, an analog of hypoxanthine, is widely used as an antigout drug, as xanthine oxidoreductase-mediated metabolism of allopurinol to oxypurinol leads to oxypurinol rotation in the enzyme ...
Mai Sekine, Ken Okamoto, Emil F Pai
exaly +7 more sources
Eicosapentaenoic acid and oxypurinol in the treatment of muscle wasting in a mouse model of cancer cachexia. [PDF]
Cancer cachexia is a wasting condition, driven by systemic inflammation and oxidative stress. This study investigated eicosapentaenoic acid (EPA) in combination with oxypurinol as a treatment in a mouse model of cancer cachexia. Mice with cancer cachexia
Vanessa C Vaughan +4 more
doaj +3 more sources
The impact of genetic variability in urate transporters on oxypurinol pharmacokinetics
The genetic determinants of the allopurinol dose‐concentration relationship have not been extensively studied. We aimed to clarify what factors, including genetic variation in urate transporters, influence oxypurinol pharmacokinetics (PKs).
Hailemichael Z. Hishe +6 more
doaj +3 more sources
Oxypurinol protects renal ischemia/reperfusion injury via heme oxygenase-1 induction [PDF]
Renal ischemia/reperfusion (I/R) injury is a major cause of acute kidney injury (AKI) by increasing oxidative stress, inflammatory responses, and tubular cell death.
Hye Bin Kang +3 more
doaj +2 more sources
Allopurinol non-covalently facilitates binding of unconventional peptides to HLA-B*58:01 [PDF]
Allopurinol, widely used in gout treatment, is the most common cause of severe cutaneous adverse drug reactions. The risk of developing such life-threatening reactions is increased particularly for HLA-B*58:01 positive individuals.
Xuelu Huan +3 more
doaj +2 more sources
Oxypurinol pharmacokinetics and pharmacodynamics in healthy volunteers: Influence of BCRP Q141K polymorphism and patient characteristics [PDF]
The missense variant, breast cancer resistance protein (BCRP) p.Q141K, which encodes a reduced function BCRP, has been linked to poor response to allopurinol.
Bianca Vora +6 more
doaj +2 more sources
Screening and functional verification of potential metabolites for high fertility in sows [PDF]
BackgroundNutritional metabolism greatly influences the embryonic development and pregnancy outcomes. Exploring the metabolic differences between high and low fertility individuals plays pivotal roles in improving reproduction in mammals.ObjectiveThe ...
Ran Ning +19 more
doaj +2 more sources
Impact of Oxypurinol in Patients With Symptomatic Heart Failure
ObjectivesThis study evaluated whether a xanthine oxidase (XO) inhibitor, oxypurinol, produces clinical benefits in patients with New York Heart Association functional class III to IV heart failure due to systolic dysfunction receiving optimal medical ...
Hare, Joshua M. +9 more
openaire +2 more sources
A fixed dose combination of lesinurad and allopurinol has been recently approved by USFDA and EMA for treatment of gout-associated hyperuricemia in patients who have not achieved target serum uric acid levels with allopurinol alone.
Muzaffar Iqbal +3 more
doaj +2 more sources

